Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine, Octreotide and Albumin in Refractory Ascites
NCT00240045Phase 3Completed
- Sponsor
- University of Alberta
- Start
- Oct 2005
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of midodrine, Octreotide long-acting injection and albumin (human) in Type 2 Hepatorenal Syndrome and ascites, sponsored by University of Alberta. Primary endpoint: Improvement in renal function (creatinine) at 1 month. Started Oct 2005; status: completed.
02
Drugs
midodrineOctreotide long-acting injectionalbumin (human)
03
Conditions
Type 2 Hepatorenal Syndromeascites
Beyond the preview
Go deeper on NCT00240045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240045.